That holds in the United States as it does everywhere: the phrase treatment-resistant carries a specific meaning, and it only applies after documented trials at appropriate doses and durations. Anyone comparing the United States programmes will find this decisive: a separate line of research has examined rapid reduction in suicidal ideation specifically, which is a distinct question from sustained treatment of depression. Read against the United States market, uncontrolled hypertension is treated as a serious caution for a straightforward physiological reason, and a programme that does not check blood pressure before dosing has skipped a step. In practice this means a single infusion in the United States commonly falls between four hundred and eight hundred dollars, putting a six-session induction somewhere near two and a half to five thousand.
Approval for esketamine extends to depressive symptoms in adults with major depressive disorder and acute suicidal ideation, a narrow and specific indication rather than a general one. Legitimate programmes respond to the abuse potential with structure rather than reassurance: observed administration, no take-home injectable supply and defined session intervals. Nothing about the United States changes that. Six infusions over roughly three weeks is the common induction pattern, though some programmes offer four and others extend to eight. It is the first thing to establish about any the United States programme. Provider backgrounds in this field vary more than in almost any other corner of medicine, which is why credentials repay a closer reading than usual. That is as true in the United States as anywhere else in the country. The trial protocols that produced the evidence base were run in monitored medical environments, and the monitoring was part of what made them safe rather than an accessory to it. The United States listings on this page are organised so that this is checkable rather than assumed.
A standard induction course in most American clinics runs to six sessions delivered over two to three weeks, though the number is a convention inherited from early trial protocols rather than a figure settled by comparative research. Some people are offered four; some programmes run to eight. What happens after induction is the genuinely unresolved part of the field. Response, where it occurs, is often not permanent, and many patients move onto a maintenance schedule of a single session every two to six weeks. Any clinic that presents six infusions as a complete and finished course without discussing what maintenance might look like, and what it might cost over a year, is describing half the treatment.
Where the evidence is strong and where it thins out
For anyone weighing options in the United States, a clinic that agrees to treat anyone who asks, without reference to what has already been tried, has replaced clinical judgement with a booking system. Where the evidence is strongest concerns short courses in adults who have not responded to at least two adequate antidepressant trials. It is worth carrying that into every conversation with a the United States provider. A clinic willing to escalate frequency on request, or to supply product without meaningful assessment, has removed the safeguards that keep the risk manageable. In the United States the same rule applies: cost is the constraint that settles the question for a large share of people, which makes the reluctance to publish prices worth noticing.
There is a specific population for whom this conversation is most relevant, and it is narrower than the advertising implies. The trial evidence concentrates on adults with major depressive disorder who have not responded adequately to at least two antidepressant trials at appropriate doses and durations. If someone has never tried a first-line treatment, the reasonable clinical answer is usually to start there, because the evidence is stronger, the cost is lower and the risk profile is better understood. A clinic that agrees to treat anyone who asks, without reference to what has been tried, has replaced clinical judgement with a booking system.
A fair reading of the literature is that this is a promising option for a defined population rather than an established standard of care for everyone. Patients researching the United States providers run into this constantly. The gap between anaesthetic and psychiatric dosing is large enough that describing them as the same treatment obscures more than it explains. Applied to the United States, the point is this: the clinics that treat this as a psychiatric treatment rather than a procedure tend to build psychological support into the protocol rather than offering it as an upsell. A consultation that moves quickly from hello to a package price has skipped the assessment that determines whether treatment is appropriate at all. Search results for ketamine treatment in the United States return a remarkably uniform set of pages, which makes genuine comparison harder rather than easier. Ketamine is a Schedule III controlled substance, which formally recognises a potential for misuse and shapes how responsible programmes are structured. The United States listings on this page are organised so that this is checkable rather than assumed.
What a properly run programme looks like from the inside
Read against the United States market, randomised controlled trials have reported rapid reductions in depressive symptom scores after subanaesthetic infusions, often visible within hours to days rather than the weeks conventional antidepressants require. Screening should cover cardiovascular history, personal and family history of psychosis or bipolar disorder, hepatic function, substance use history and current medications. Nothing about the United States changes that. Applied to the United States, the point is this: commercial insurance seldom reimburses off-label intravenous administration, though the associated psychiatric evaluation is sometimes billable and worth asking about specifically. Coordination with an existing prescriber is a marker of considered practice, even though it slows the path to a first appointment.
Every the United States programme is operating inside the same clinical framework, which runs as follows. In 2023 the FDA issued a public warning about compounded ketamine products used at home without monitoring, citing risks including sedation, dissociation, airway compromise and the absence of any clinician present if something goes wrong. That warning is the clearest available signal about where the regulatory line sits. Telehealth has a legitimate and useful role in this field for consultation, screening, follow-up and integration therapy, and it materially improves access for people far from a metropolitan clinic. Using it to mail a dissociative anaesthetic to an unmonitored patient is a different proposition, and the distinction is worth insisting on.
In the United States the same rule applies: if the neuroplasticity hypothesis is right, what happens between sessions is not an optional extra but part of how the treatment is meant to function. Weight-based dosing in the region of 0.5 milligrams per kilogram over roughly forty minutes is the convention, though clinics vary in whether they adjust it between sessions. That holds in the United States as it does everywhere: the trial evidence is real and also limited: studies tend to be small, follow-up periods short, and blinding is notoriously difficult when the dissociative effect is obvious to participants. What people looking at the United States providers usually want is the operational detail, and that is precisely what clinic marketing tends to omit.
How to decide without guessing
For anyone weighing options in the United States, a history of psychosis or a bipolar diagnosis changes the risk calculation substantially, which is why a thorough intake asks about family psychiatric history and not only personal history. Asking for an annualised cost rather than a per-session figure produces a far more useful number and occasionally a revealing pause. The population the trial evidence covers is narrower than the advertising implies, concentrating on adults who have not responded to at least two adequate antidepressant trials. It is the first thing to establish about any the United States programme. The honest summary is that the short-term findings are encouraging and the long-term picture remains genuinely unsettled. It is worth carrying that into every conversation with a the United States provider.
Before comparing anything specific to the United States, the underlying clinical picture is worth stating properly. Ketamine is a Schedule III controlled substance in the United States, and that legal status shapes the entire delivery landscape. It means the drug carries a recognised potential for misuse and dependence. Legitimate programmes respond to that with structural safeguards rather than reassurance: doses administered on site and observed, no take-home supply of injectable product, defined session intervals, and screening that takes substance use history seriously rather than treating it as a formality. A programme willing to escalate frequency on request, or to ship product without meaningful assessment, has removed the guardrails that make the risk manageable.
Solid food is usually restricted for several hours beforehand, largely to limit nausea during administration. The infusion can be slowed or stopped if someone becomes distressed, and knowing that in advance is itself a meaningful part of preparation. That is as true in the United States as anywhere else in the country. What happens financially if treatment is stopped partway through is a question best asked before the first session rather than after the third. Patients researching the United States providers run into this constantly. Integration, the structured work of making sense of a session afterwards, is the element most often missing from purely procedural clinics. In practice this means anyone searching for treatment in the United States meets the same wall of interchangeable clinic websites, all promising personalised care and none explaining what that means operationally. Screening should cover cardiovascular history, personal and family history of psychosis or bipolar disorder, hepatic function, substance use history and current medications.
The questions that separate good clinics from glossy ones
Anyone comparing the United States programmes will find this decisive: the headline per-session price usually excludes the consultation, any separately billed psychiatric evaluation, integration therapy and the maintenance sessions that follow. Someone who has not yet tried a first-line treatment is usually better served starting there, where the evidence is stronger, the cost lower and the risk profile better understood. That holds in the United States as it does everywhere: the trial evidence is real and also limited: studies tend to be small, follow-up periods short, and blinding is notoriously difficult when the dissociative effect is obvious to participants. Uncontrolled hypertension is treated as a serious caution for a straightforward physiological reason, and a programme that does not check blood pressure before dosing has skipped a step.
The background that makes the United States listings interpretable is this. The evidence base deserves an honest summary rather than either dismissal or enthusiasm. Multiple randomised controlled trials have found rapid reductions in depressive symptom scores following single and repeated subanaesthetic ketamine infusions, with effects often visible within hours to days rather than weeks, and a separate line of research has examined rapid reduction of suicidal ideation specifically. Those are real findings from real trials. The significant limitations are equally real: many studies are small, blinding is notoriously difficult because the dissociative effect is obvious to participants, follow-up periods are usually short, and the question of what happens over years of maintenance has not been answered. A reasonable reading is that this is a promising and genuinely useful option for a specific population, not a settled standard of care for everyone.
In 2023 the FDA warned publicly about compounded ketamine used at home without monitoring, citing sedation, dissociation and airway risk with no clinician present. A clinic that agrees to treat anyone who asks, without reference to what has already been tried, has replaced clinical judgement with a booking system. Put plainly, a single infusion in the United States commonly falls between four hundred and eight hundred dollars, putting a six-session induction somewhere near two and a half to five thousand. Transient elevation in blood pressure and heart rate is expected, which is the reason monitoring runs continuously rather than at intervals. In the United States the same rule applies: whether a programme titrates the dose according to response and tolerability, or runs a fixed protocol for everyone, is a meaningful difference in how individualised the care actually is.
Risks, contraindications and honest caution
A clinic that agrees to treat anyone who asks, without reference to what has already been tried, has replaced clinical judgement with a booking system. The trial evidence is real and also limited: studies tend to be small, follow-up periods short, and blinding is notoriously difficult when the dissociative effect is obvious to participants. Legitimate programmes respond to the abuse potential with structure rather than reassurance: observed administration, no take-home injectable supply and defined session intervals. Anyone comparing the United States programmes will find this decisive: asking for an annualised cost rather than a per-session figure produces a far more useful number and occasionally a revealing pause.
What follows applies to the United States and to every other market, and it is the part worth reading slowly. Preparation shapes the experience more than most people expect. Clinics typically ask patients to avoid solid food for several hours beforehand, largely because of nausea, and to arrange a ride home, because driving is off the table for the remainder of the day. Beyond the logistics, the psychological preparation matters: going in with a settled expectation that the dissociative period is temporary, expected and monitored tends to make it far less alarming than encountering it cold. People who have discussed in advance what they will do if they feel frightened, and who know that the infusion can be slowed or stopped, generally describe a calmer experience than those who have not.
The practical difference is that esketamine is approved and more often insurable but less flexible, while intravenous ketamine is off-label, usually self-funded and more adjustable. The headline per-session price usually excludes the consultation, any separately billed psychiatric evaluation, integration therapy and the maintenance sessions that follow. Nothing about the United States changes that. Each session occupies roughly two hours on site once administration, monitoring and recovery are counted, which is longer than most people budget for. That is as true in the United States as anywhere else in the country. Read against the United States market, antagonism at the N-methyl-D-aspartate receptor appears to trigger a downstream cascade involving brain-derived neurotrophic factor and increased synaptic connectivity in mood-regulating regions. Randomised controlled trials have reported rapid reductions in depressive symptom scores after subanaesthetic infusions, often visible within hours to days rather than the weeks conventional antidepressants require.
What to take from all of this
Travel time belongs in the treatment plan rather than being treated as a detail to solve later. It is worth carrying that into every conversation with a the United States provider. The open question in the field is durability, which is why the maintenance conversation belongs in the first consultation rather than the seventh week. The United States listings on this page are organised so that this is checkable rather than assumed. Researchers describe the result as a window of heightened neuroplasticity, which is a hypothesis with support rather than a settled account. A separate line of research has examined rapid reduction in suicidal ideation specifically, which is a distinct question from sustained treatment of depression. Patients researching the United States providers run into this constantly. Comparing programmes in the United States is difficult because the variables that decide quality are rarely the ones displayed on a homepage.
Treatment decisions of this kind belong to a person and the clinician who knows their history. What a directory can usefully do is make sure nobody walks into that discussion missing something they needed.
This page is general information, not medical advice, and no directory can assess whether a treatment is appropriate for an individual. Ketamine is a controlled substance with genuine risks, and its use for mood disorders is off-label apart from esketamine, which holds FDA approval for treatment-resistant depression under a restricted programme. Decisions about treatment should be made with a qualified clinician who knows your full history. If you are in crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988 in the United States, or go to your nearest emergency department.